Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) Sternberg, P., AABERG, T. M., Martin, D., Saperstein, D., Hyatt, M., Gilman, J., SWORDS, R., Nemes, G., Singerman, L. J., Rice, T. A., Zegarra, H., Novak, M. A., Pendergast, S., Zakov, Z. N., Niffenegger, J., Bartel, M., LICHTERMAN, S., Knight, D., Tilocco-DuBois, K., Ilk, M., Daley, G., Greanoff, G., Dubois, J., Weiss, D., Lyon, A., Jampol, L., Weinberg, D., Chiapetta, B., Strugala, Z., Richine, L., Fish, G. E., Callanan, D., JOST, B., Anand, R., Snyder, W. B., Fuller, D., ANDERSON, T., Arceneaux, S., AGUADO, H., NORK, C., Boleman, B., Avery, P., Solomon, S., KING, J., Orth, D., Packo, K., Cohen, J., DEBUSTROS, S., Figliulo, C., Morrison, C., Lluen-Johnson, K., Bryant, D., Doherty, D., Folk, J., Boldt, H. C., Gehrs, K., Russell, S., Fountain, C., Griffin, M., Heffron, E., Vogel, C., Ward, B., Northway, R., Sabates, F., Schuchard, R., Sabates, N., Poulose, A., Crosser, V., Matta, C., Keeling, M., Lei, H., Gallimore, G., Holz, E. R., Wood, W., Isernhagen, R., Wolfe, J., Hawkins, L., Taul, Y., Oldroyd, M., Cornett, L., Van Arsdall, J., SLADE, E., Harris, M., Chandra, S., Stevens, T., Meyers, F., Olsen, T., Blodi, B., Gottlieb, J., Walker, W., Perry, J., Knutson, G., Harrison, R., Neider, M., Wabers, H., Little, H., Blumenkranz, M., Jack, R., Zweng, H. C., Showman, J., Hahn, T., JIMENEZ, L., Mattio, P., Cabrera, O., Gitter, K., Cohen, G., Ross, R., Newell, K., Schomaker, K., Fine, S. L., Brucker, A., Ho, A. C., Maguire, A., GRUNWALD, J., Dupont, J., Kirschner, J., Sterling, E., Goller, G., Sheehan, M., Nyberg, B., Weeney, L., Reynolds, J., Elkins, D., Klein, M., Wilson, D., Nolte, S., Evans, M., Wallace, P., MARGHERIO, R. R., TRESE, M. T., Hassan, T. S., Margherio, A., Capone, A., CUMMING, K., Mitchell, B., STREASICK, P., Bridges, C., Huston, G., Szydlowski, L., Medina, T., McDonald, H. R., SCHATZ, H., Johnson, R., Ai, E., Wood, P., Di Angelo, M., Stolarczuk, M., Rosenfeld, I., Wild, S., Uy, J., Maguire, M. G., Ying, G. S., Brightwell-Arnold, M., Stanford, N. N., Dallas, V., Wheary, C., Fine, S. L., Reich, A., Fatula, E., Katz, M., Ho, A. C., Javornik, N. B., Alexander, J., Begley, S., Elsner, K. S., McWilliams, K. C., Whitlock, E. R., FINKELSTEIN, D., Hawkins, B. S. ELSEVIER SCIENCE INC. 2003: 971–78

Abstract

To update the findings from the Choroidal Neovascularization Prevention Trial (CNVPT) with respect to resolution of drusen, incidence of choroidal neovascularization, and visual function.A multicenter, randomized, controlled, pilot clinical trial.The 120 patients enrolled in the CNVPT. Patients had signs of choroidal neovascularization or retinal pigment epithelial detachment in 1 eye and had >/=10 large (>63- micro m) drusen in the contralateral, or fellow, eye.The fellow eye of 59 patients was assigned randomly to argon green laser treatment consisting of multiple 100- micro m spots at least 750 micro m from the center of the fovea. The fellow eye of the remaining 61 patients was assigned randomly to observation.Change in visual acuity was the primary outcome measure. Incidence of choroidal neovascularization, resolution of drusen, change in contrast threshold, change in critical print size for reading, and incidence of geographic atrophy were secondary outcome measures.Throughout 4 years of follow-up, there were no statistically significant differences in change in visual acuity, contrast threshold, critical print size, or incidence of geographic atrophy. With additional follow-up, the large increase in the incidence of choroidal neovascularization observed within 18 months of treatment was maintained; however, by 30 months, the incidence in the two treatment groups was the same. Most drusen resolution in treated eyes occurred within 24 months of the initial treatment. Treated eyes that received higher-intensity laser burns had an increased risk of choroidal neovascularization. Among eyes developing choroidal neovascularization in each treatment group, most lesions (two thirds or more) were composed of occult neovascularization only.Laser treatment as applied in the CNVPT caused an excess risk of choroidal neovascularization in the first year or so after treatment. The increased early incidence of choroidal neovascularization was not associated with either a harmful or beneficial effect in this pilot study.

View details for DOI 10.1016/S0161-6420(03)00098-8

View details for Web of Science ID 000182754600031

View details for PubMedID 12750100